MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa

Дата публикации: 01-10-2026 09:32:09

Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS	0	8.71	30-09-2026
2	Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	0	11.04	15-12-2025
3	Galderma’s Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis	0	21.96	02-10-2026
4	Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps	0	12.24	17-02-2026
5	Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)	0	8.93	08-04-2026
6	Two investigational agents for wet AMD meet primary endpoints	0	12.49	28-09-2026
7	Препарат Ogsiveo рекомендован NICE для лечения редких опухолей мягких тканей	0	8.88	30-09-2026
8	ГК «ХимРар» запускает программу раннего доступа к терапии РМЖ инновационным препаратом биреоциклиб	0	9.4	30-09-2026
9	Arctic Sea Cucumber Delivers One-Two Punch to Triple-Negative Breast Cancer	0	8.88	29-09-2026
10	Remigromig meets endpoint in phase 2b/3 DME trial	0	9.16	25-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.35. Источник: www.pmlive.com.